Transcription of PRODUCT MONOGRAPH INCLUDING PATIENT …
{{id}} {{{paragraph}}}
Example: marketing
PRODUCT MONOGRAPH INCLUDING PATIENT …
Casirivimab and imdevimab for injection Page 1 of 26 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCasirivimab and imdevimab for injection Solutions for infusion, each available as 1332 mL and 300 mL (120mg/mL) single-use vials Anti-SARS-CoV-2 spike protein monoclonal antibodies HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS COVID-19 DRUG BASED ON LIMITED CLINICAL TESTING IN HUMANS AND/OR QUALITY INFORMATION Casirivimab and imdevimab are indicated for: Casirivimab and imdevimab, to be administered together, are indicated for the treatment of mild to moderate coronavirus disease 2019 (COVID-19), confirmed by direct SARS-CoV-2 viral testing, in adults and adolescents (12 years of age and older weighing at least 40 kg) who are at high-risk for progressing to hospitalization and/or death.
INCLUDING PATIENT MEDICATION INFORMATION PrCasirivimab and imdevimab for injection Solutions for infusion, each available as 1332 mg/11.1 mL and 300 mg/2.5 mL (120mg/mL) single-use vials Anti-SARS-CoV-2 spike protein monoclonal antibodies HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS COVID-19 DRUG BASED ON LIMITED CLINICAL
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: